TrialJAMA neurology2023

Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Angela Genge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.